Correlated research between protein spectrometry and lymphoma markers for DLBCL patients
10.3760/cma.j.issn.1009-9921.2008.02.005
- VernacularTitle:弥漫大B细胞淋巴瘤患者蛋白质谱与淋巴瘤标志物表达的相关性研究
- Author:
Qi ZHANG
;
Qiaohua ZHANG
;
Shuling HOU
;
Jun WANG
;
Jianxia HE
;
Sutong GUO
;
Yuping ZHENG
;
Weie HAN
;
Lieyang WANG
;
Bin YANG
- Publication Type:Journal Article
- Keywords:
Lymphoma,large-cell,diffuse;
LDH;
β2-MG;
CA125;
Spectrometry,mass,matrix-assisted laser desorption-inoization
- From:
Journal of Leukemia & Lymphoma
2008;17(2):94-97
- CountryChina
- Language:Chinese
-
Abstract:
Objective To research correlation of serum protein spectrometry and lymphoma markers for diffuse large B cell lymphoma (DLBCL) patients. Whether there is relative between the protein and prognosis will be further researched. Methods Serum protein spectrometry of 62 DLBCL patients was detected by the SELDI-TOF-MS technique and Weak cation exchange 2 (WCX2) chip. Lactate dehydrogenase (LDH) was detected by biochemistry method. Beta-2-microglobulin (β2-MG) and cancer antigen125(CA125)were detected by enzyme-linked immunosorbent assay (ELISA). The level of LDH, β2-MG and CA125 for DLBCL patients between 11×103～12×103 protein expressed positively and negatively was analyzed. Meanwhile,correlation analysis and survival analysis were done. Results LDH, β2-MG and CA125 in 11×103～12×103protein expressed positive group were (523.30±435.96)U/L, (3.23±1.24)mg/L, (81.07±61.39)U/L respectively,and they were higher than that in negative group (P＜0.05). 11×103～12×103 protein was positive correlated to LDH, β2-MG and CA125 (P＜0.01). The survival time in 11×103～12×103 protein expressed in positive group,in which median survival time was 11 months, was shorter than that in negative group(P ＜0.01). The survival time in LDH normal group was longer than that in increased group(P ＜0.01). The survival time of β2-MG and CA125 had no significant difference between increased group and normal group. Conclusion LDH and 11×103～12×103 protein are expected to be prognosis indicators for DLBCL patients.
